Cybin Inc. CLXPF Archives - Page 5 of 5

TuesdayApr 06, 2021 1:21 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Completes Pre-Clinical Studies, Progresses Two Drug Candidates

Cybin has completed more than 20 pre-clinical studies in record time. Company is advancing two new therapeutic candidates with enhanced, improved properties. Drug candidates are designed to treat serious psychiatric conditions with high unmet medical needs. Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, has completed key research studies both in vitro and in vivo. The company recently announced that it had completed its 20th pre-clinical study and had progressed two psychedelic investigational new drug candidates: CYB003 and CYB004 (https://ibn.fm/jDvFz). The studies were completed in record time, the company reported, in part because of close collaboration with…

TuesdayMar 30, 2021 9:58 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Appoints New Management Positions, Focused on Development and Clinical Operations

Cybin (NEO: CYBN) (OTCQB: CLXPF) announced changes in senior management positions. Cybin US Holdings Inc.’s new chief clinical officer will be Alexander Belser, PhD and its new chief operating officer will be Aaron Bartlone. In addition, co-founder and former COO Paul Glavine has been named chief growth officer and co-founder of Cybin Inc., while former SVP of business development John Kanakis will become chief business officer. The changes are effective immediately. An accomplished biopharmaceutical executive with a proven track record across numerous therapeutic and functional areas, Bartlone has extensive experience with quality assurance, regulatory affairs, product development, compliance and commercial…

MondayMar 22, 2021 10:40 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Enters Strategic Drug Development Agreement with Catalent Inc. (NYSE: CTLT)

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced its entry into a drug development agreement with Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. According to the update, Cybin will be applying Catalent’s proprietary Zydis(R) orally disintegrating tablet (“ODT”) technology for the delivery of its novel deuterated tryptamine (“CYB003”), a potential therapy for treatment-resistant psychiatric disorders. “We are excited to partner with the team at Catalent with the aim of developing fast-acting, shorter-duration formulations of…

TuesdayMar 16, 2021 12:01 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at Oppenheimer Health Care Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the Oppenheimer 31st Annual Healthcare Conference. Drysdale’s presentation is scheduled to begin at 11:20 a.m. Eastern Time on Thursday, March 18, 2021. Interested parties should visit https://ibn.fm/ZE9G5 to register for the event. The presentation will be webcast live at the aforementioned time and available for seven days thereafter via the above link. To view the full press release, visit https://ibn.fm/6i8Iw About Cybin Inc. Cybin is a leading biotechnology company…

MondayMar 15, 2021 10:10 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at 2021 Emerging Growth Virtual Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the M Vest and Maxim Group 2021 Emerging Growth Virtual Conference slated to take place from March 17-19, 2021. In addition, Drysdale will participate on the psychedelics panel beginning at 3:30 p.m. ET on Wednesday, March 17. Interested parties should visit https://ibn.fm/MjGa2 for more information regarding the event. The panel discussion will be webcast live at the aforementioned time and available for seven days thereafter via the above link. To…

WednesdayMar 10, 2021 12:48 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at Stifel GMP Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the Stifel GMP Health Care Conference – Health Care Psychedelics: Addressing the Global Mental Health Crisis. Drysdale’s presentation is scheduled to begin at 1:00 p.m. Eastern Time on Thursday, March 11, 2021. The presentation will be webcast live at https://ibn.fm/yLkYT and available for seven days following the event. To view the full press release, visit https://ibn.fm/XvtFx About Cybin Inc. Cybin is a leading biotechnology company focused on progressing psychedelic…

MondayMar 08, 2021 10:37 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Commences Trading on the OTCQB(R) Venture Market

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its shares have commenced trading on the OTCQB(R) Venture Market under the symbol “CLXPF.” “With the commencement of trading on the OTCQB, Cybin has achieved another important milestone on its path to advancing mental health care through evidenced-based therapeutics. This additional capital markets exposure offers us greater visibility within the investment community, which should enhance our liquidity and increase our access to institutional and retail investors,” said Doug Drysdale, CEO of Cybin. “This support is extremely valuable to us as we continue to progress…

ThursdayMar 04, 2021 12:11 pm

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) Newly Acquired Subsidiary Achieves Earn-Out Milestone —Successful Synthesis of Multiple Tryptamine Derivatives

Adelia Therapeutics has achieved earn-out milestones outlined in contribution agreement with Cybin Adelia ideal acquisition for Cybin, as it leads innovation in researching psychedelic treatment options in the mental health space Acquisition results in Cybin obtaining extensive intellectual property portfolio and product pipeline Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, has announced that its recently acquired subsidiary, Adelia Therapeutics Inc., has achieved the earn-out milestones outlined for the time period in the contribution agreement between the two companies (https://ibn.fm/c6o2E). That milestone includes the successful synthesis of multiple tryptamine derivatives.…

WednesdayMar 03, 2021 9:46 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTC: CLXPF) to Commence Trading on the OTCQB Venture Market

Cybin (NEO: CYBN) (OTC: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced its successful uplisting from the OTC Pink Sheets to the OTCQB(R) Venture Market. Cybin will commence trading on the OTCQB under the symbol “CLXPF” at market open on March 8, 2021. “Listing on the OTCQB is another important milestone for Cybin. It affords us greater visibility within the investment community, which should enhance our liquidity and increase our access to institutional and retail investors,” said Doug Drysdale, CEO of Cybin. “This additional capital markets exposure will be valuable as we continue to support our psychedelic…

Site Search

Company Search

Tag: Cybin Inc. CLXPF